Introduction
Extensive research over the past two decades has established that cancer in humans arises from a cell that has acquired multiple genetic alterations in oncogenes and/or tumor suppressor genes (Weinberg, 1989; Fearon and Vogelstein, 1990; Hunter, 1991) . Mutations and/or altered expression of these critical genes and their downstream eector genes allow a cell to escape from normal growth control and become malignant. A direct comparison of gene expression between non-tumorigenic and tumorigenic cells of the same genetic background should provide information on genetic changes involved in the transformation process. Subsequent cloning and functional analysis of these dierentially expressed genes may enrich our understanding of cancer development.
To study the molecular mechanisms underlying neoplastic transformation of human cells, we used the near-diploid, karyotypically stable, in®nite life span human ®broblast cell strain MSU-1.1 as a model system. Cell strain MSU-1.1 was established in this laboratory from a normal diploid human neonatal foreskin ®broblast cell line (Morgan et al., 1991) . The cells are phenotypically normal and do not form tumors in athymic mice. Transfection of MSU-1.1 cells with an activated ras oncogene expressed at high levels (Hurlin et al., 1989; Wilson et al., 1990) or treatment of the cells with chemical carcinogens, such as (+)-7b,8a-dihydroxy-9a,10a-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene (BPDE) followed by selection for focus-forming cells (Yang et al., 1992) results in transformants capable of tumor formation in athymic mice. However, the molecular basis of the neoplastic conversion in MSU-1.1 cells by treatment with chemical carcinogens is not understood. To identify putative oncogene(s) and tumor suppressor gene(s), as well as other types of genes associated with malignant transformation, we used dierential mRNA display (Liang and Pardee, 1992; Liang et al., 1993) to compare the pro®le of gene expression in parental cell strain MSU-1.1 and cell line 6A/SB1. The latter was derived from a ®brosarcoma formed in an athymic mouse by a BPDE-transformed MSU-1.1 cell strain. One of the dierentially expressed genes identi®ed corresponds to ®bulin-1D, an extracellular matrix (ECM) and plasma protein (Argraves et al., 1990; Tran et al., 1997) . It is expressed at high levels in MSU-1.1 cells and is markedly down-regulated in 6A/ SB1 cells. Analysis of 16 cell lines established from tumors formed in athymic mice by MSU-1.1-derived cell strains transformed in culture by various agents showed that seven (44%) had a low level or complete lack of expression of ®bulin-1D mRNA and protein.
Similarly, analysis of 15 cell lines derived from tumors taken from patients showed that 12 (80%) had a low level or complete lack of expression of this mRNA and protein.
To determine if low expression of ®bulin-1D were causally involved in the malignant transformation of these cell lines, we studied the eect of stably expressing ®bulin-1D in human ®brosarcoma-derived cell line SHAC and in 6A/SB1 cells, which lack the expression of this protein. The results showed that elevated expression of ®bulin-1D signi®cantly decreased the anchorage-independent growth of both SHAC and 6A/SB1 cell derivatives, as well as their invasiveness when tested in a matrigel in vitro invasion assay, and signi®cantly delayed the onset of tumor formation in athymic mice by these cell lines.
Results

Identi®cation of ®bulin-1D as a dierentially expressed mRNA
To identify transformation-related genes, we carried out dierential mRNA display analysis, comparing the non-tumorigenic parental MSU-1.1 cell strain and a tumorigenic derivative cell line, 6A/SB1. RT ± PCR reactions were carried out using 80 dierent combinations of primer sets, composed of four degenerate anchored oligo(dT) primers, T 12 MN (M was dG, dC or dA; N was dG, dC, dA or dT) and 20 arbitrary 10-mers (OPA 1-20, Operon Technologies, Alameda, CA). About 8000 bands were observed. The band pattern for cell line 6A/SB1 diered from that of parental MSU-1.1 in nine bands, each of which was down-regulated in 6A/SB1 cells. These cDNAs were excised from the sequencing gel, reampli®ed by PCR, and used as probes for Northern blot analysis. Such analysis showed that only ®ve of these nine dierentiallydisplayed cDNAs represented mRNAs that actually are expressed at signi®cantly lower levels in the 6A/SB1 cells as compared with the MSU-1.1 cells. One of the ®ve unique bands, designated SG7, is characterized in this report. As shown in Figure 1b , this cDNA hybridized to a 2.7 kb transcript showing a 14-fold lower level of expression in 6A/SB1 cells than in MSU-1.1 cells. Cloning and sequencing of this partial cDNA indicated that it consisted of 311 base pairs and was 98.7% identical to an expressed sequence tag (Genbank accession No. T19384).
To get the full-length cDNA corresponding to SG7, EST clone T19384 was obtained from the investigator who reported it, Dr Georges Guellaen (Hopital Henri Mondor, Creteil, France), and the 5' and the 3' regions of the EST clone were sequenced. A database search revealed that the EST corresponded to the human ®bulin-1D gene, with 97.4% identity in a 312 bp overlap in the 5' region (bases 1 ± 312 of ®bulin-1D) and 98.9% identity in a 188 bp overlap in the 3' region (bases 2172 ± 2359 of ®bulin-1D). The SG7 cDNA that we isolated by dierential display contained a sequence that extended beyond the 3' sequence of the ®bulin-1D cDNA sequence deposited in the database.
To con®rm the identity of SG7 as human ®bulin-1D, we carried out Northern blot analysis using the 2.3 kb human ®bulin-1D cDNA insert from plasmid pBluescriptSK®bulin1D (Tran et al., 1997) to probe the same membrane previously used to detect SG7 expression. As shown in Figure 1c , the ®bulin-1D cDNA probe detected the 2.7 kb mRNA transcript that had been detected by SG7 (Figure 1b ), but it also detected a 2.3 kb mRNA transcript which corresponds to ®bulin-1C. This is consistent with the fact that these two mRNAs have identical 5' regions (bases 1 ± 1707). Both transcripts exhibited coordinately decreased expression in 6A/SB1 cells compared with the parental MSU-1.1 cells.
Expression analysis of ®bulin-1D in multiple human tumor cell lines
To test whether the decreased expression of ®bulin-1D transcript is a common feature of human tumor cells, we carried out Northern analysis using ®bulin-1D cDNA as a probe with RNA from 15 cell lines derived from malignant tumors taken from patients and 16 cell lines established from tumors produced in athymic mice by MSU-1.1-derived cell strains transformed in Table 1 . Examples of results are shown in Figure 2 . Very low levels of expression of ®bulin-1 were found in ®ve out of ®ve ®brosarcoma-derived cell lines (lanes 15 ± 19), in two out of two osteosarcoma-derived cells (lanes 8 and 9), in two out of three neuro®brosarcoma-derived cells (lanes 12 and 20), in one out of two human bladder carcinoma-derived cells (lane 11), and in the rhabdomyosarcoma-and cervical carcinomaderived cell lines (lanes 7 and 10) tested in this study. Downregulation of ®bulin-1 mRNA expression was also found in six out of 15 MSU-1.1 lineage-derived tumor cells (lanes 3 ± 6 and 22 ± 23), in addition to cell strain 6A/SB1, in which the downregulation was ®rst identi®ed (Figure 1 ). Taken together, 19 out of 31 tumor-derived cell lines exhibited low or no expression of ®bulin-1 (C and D transcripts).
To determine whether mRNA levels correlate with ®bulin-1 protein expression, we performed Western blot analysis of cell extracts and their serum-free conditioned culture media. As a control, puri®ed ®bulin-1 protein from human placenta was included in each assay. As shown in Figure 3 , lane 1, under nonreducing conditions, mouse anti-human ®bulin-1 monoclonal antibody 3A11 speci®cally recognized the ®bulin-1 protein (apparent molecular weight, 80 kDa). We found that, consistent with results from Northern analysis, the expression of ®bulin-1 protein was very low or undetectable in a panel of tumor cell lines, not only in the cell extracts (Figure 3a) , but also in their conditioned culture media (Figure 3b) , whereas a neonatal foreskin-derived human ®broblast line, LG1, and MSU-1.1 cells expressed high levels of ®bulin-1 proteins. The presence of multiple immunoreactive polypeptides that migrated faster than the mature ®bulin-1 polypeptide on SDS ± PAGE (Figure 3a ) may correspond to proteolytic fragments of ®bulin-1. Similar fragments have been observed in puri®ed ®bulin-1 preparations derived from placenta and lung Fibulin 1C
LG1 MSU-1.1 Table 1 . (b) RNA loading, evaluated by rehybridizing the same blots with a GAPDH cDNA probe Fibulin-1D suppresses invasion and tumorigenicity J Qing et al and have been generated in vitro by matrilysin and leucocyte elastase digestion (Sasaki et al., 1996) .
Establishment of SHAC and 6A/SB1 clones stably expressing high levels of ®bulin-1D protein
The level of ®bulin-1 protein in either cell extracts or conditioned media (Figure 3 ) from ®brosarcoma-derived cell lines SHAC and 6A/SB1 is almost undetectable. To examine the eect of ®bulin-1D expression on malignant transformation, we constructed a human ®bulin-1D cDNA expression vector, designated pPuro-Fibulin-1D, and transfected it into SHAC and 6A/SB1 cells. Puromycin resistant clones were isolated from cells that were the result of independent transfection events, i.e. from independent dishes. Immunoblot analysis of whole cell extracts was used to identify clones that expressed high levels of ®bulin-1D protein. For SHAC cells, a total of 24 clonally-derived, drug-resistant populations were tested. Five independent clones exhibited high levels of ®bulin-1D protein. Two clones of SHAC cells that had been transfected with the control vector pBABE-Puro and displayed no detectable ®bulin-1D protein were used as negative controls. The same procedure was carried out with the 6A/SB1 cells. Of 45 puromycin-resistant clones assayed, ten showed high expression of ®bulin-1D. Six independent positive clones and three vectortransfected negative control clones were selected at random for further characterization.
We also evaluated the level of ®bulin-1 secreted into the conditioned culture medium by these cell strains. As expected, neither the parental cells nor the vectortransfected control clones secreted ®bulin-1. In contrast, the transfected clones that expressed high levels of cellular ®bulin-1D secreted relatively high levels of mature proteins into the medium (Figure 4 ).
Anchorage-independent growth of the clones that express ®bulin-1D
Since most malignantly transformed cells, including SHAC and 6A/SB1 cells, exhibit anchorage-indepen- were subjected to immunoblotting analysis as described in Figure 3 . An arrow indicates the dimer of ®bulin-1D, and an arrowhead indicates the monomer Fibulin-1D suppresses invasion and tumorigenicity J Qing et al dent growth, i.e. do not require attachment to a substratum for proliferation, whereas normal human ®broblasts and MSU-1.1 cells do, we tested whether ®bulin-1D expression aects the ability of SHAC and 6A/SB1 cells to form colonies in agarose. As shown in Figure 5 and In vitro invasiveness of ®bulin-1D transfectants
To analyse the invasive potential of the ®bulin-1D transfectants, we used a modi®ed Boyden Chamber Matrigel assay. As shown in Figure 6 , the ability of the ®bulin-1D expressing transfectants to reach the bottom of the ®lters through the matrigel was reduced by 50 ± 60% compared to that of parental cells and the vectortransfected control cell strains of both SHAC cells (8al and 8b2) and 6A/SB1 cells. (CON1, CON2, CON3). Fibulin-1D suppresses invasion and tumorigenicity J Qing et al
In vivo tumorigenicity of the ®bulin-1D-expressing clones
To determine whether restoration of the expression of the ®bulin-1D gene would also suppress in vivo tumor growth, we inoculated the ®bulin-1D-expressing transfectant cell strains, their nontransfected parental cell lines, and vector-transfected controls into athymic mice and monitored the animals for growth of tumors. As shown in Figure 7 , the latency of tumor formation for the ®bulin-1D-expressing clones was longer than that of the parental cells and the vector-transfected control cell strains. For SHAC cells and their vectortransfected control cell strains, the tumor volume reached 500 mm 3 after an average of 25 days postinjection; whereas for ®bulin-1D-transfected cells, the average time was 55 days. For 6A/SB1 cells and their vector-transfected control strains, with the exception of one, the tumor volume reached 500 mm 3 after an average of 20 days postinjection; whereas the average time for four ®bulin-1D-expressing clones was 48 days, and the other two ®bulin-1D-expressing clones failed to form tumors in 3 months.
In vitro proliferation of ®bulin-1D transfectants
If the transfected cells expressing ®bulin-1D grew more slowly than the parental cells, this could explain the biological data described. To determine the doubling time of each of the ®brosarcoma-derived cell lines, the parental cells, two vector control transfectants, and three ®bulin-1D-expressing clones were allowed to grow exponentially and the number of cells was determined at several time points (Table 2) . There was no dierence in the growth rate of the SHAC cell line, its vector-transfected control cell strains, and its ®bulin-1D-expressing cell strains. For cell line 6A/SB1 and its clonal derivatives, introduction of ®bulin-1D had no consistent eect on the growth rate of these cells. The three ®bulin-1D expressing clones grew somewhat more slowly (23.8 ± 25.8 h per doubling) than the parental cells (20.2 h). One of the vector control clones, CON3, also grew at this slower rate (25.7 h), but did not exhibit a longer than normal tumor latency period. Therefore, the lengthened latency period seen in Figure 7 cannot be accounted for by a slower growth rate of the ®bulin-1D-transfectant clones.
Discussion
In the present study, using mRNA dierential display, we found that the low expression of an extracellular matrix and glycoplasma protein, ®bulin-1D, is associated with malignant transformation. High levels of ®bulin-1 expression have been reported in a wide spectrum of normal human tissues and organs (Zhang et al., 1994 ). In the experiments described here, we assayed 15 tumor cell lines derived from human cancer patients and found that 12 cell lines showed very low levels of ®bulin-1 expression. Since the normal cells from which these tumor cells were derived are not available, we cannot be certain that the low expression is the result of downregulation. However, we observed that seven out of 16 MSU-1.1-derived tumor cell lines exhibited markedly reduced levels of ®bulin-1 expression compared with the parental MSU-1.1 cells, indicating that down regulation of ®bulin-1 expression occurs relatively frequently in the transformation of human ®broblasts in culture. Our data also showed that ®bulin-1D downregulation is not speci®cally correlated with the transformation induced by particular oncogenes or by speci®c carcinogens. Southern blotting analysis revealed that the downregulation of ®bulin-1D in the MSU-1.1 cell strain derivatives cannot be attributed to gross genetic deletions or rearrangements (data not shown).
Fibulin-1, together with ®bulin-2, belongs to a family of extracellular matrix proteins (Pan et al., 1993a; Tran et al., 1997) . Alternative splicing of a ®bulin-1 precursor RNA results in four transcripts that encode polypeptide diering from each other only at the carboxyl terminal regions. The four isoforms are designated A ± D. The major forms expressed in most human tissues and cell lines in culture are ®bulin-1C and ®bulin-1D (Zhang et al., 1994; Tran et al., 1997) . Fibulin-1 proteins are multimodular proteins containing three cysteine-rich anaphylatoxinrelated segments, nine epidermal growth factor-like repeats with a consensus motif for calcium-binding, and a variable carboxyl-terminal domain (Argraves et al., 1990; Pan et al., 1993b) . Biochemical studies have shown that ®bulin-1 interacts with itself and binds other extracellular matrix proteins, including fibronec- tin (Balbona et al., 1992) , laminin, and nidogen (Pan et al., 1993b) . Immunohistochemical studies have shown that ®bulin-1 proteins are widely expressed intercellular components of connective tissues which are present in matrix ®bers and basement membranes (Roark et al., 1995) . However, until now little was known about ®bulin-1 playing a role in the process of transformation.
Since we found that the expression of ®bulin-1 was low in many tumor-derived cell lines, we sought to determine whether this low expression of ®bulin-1 is merely a consequence of malignant transformation, or whether it plays a role in the malignant transformation process. Our results with a transfected ®bulin-1D gene demonstrate that in each case (11 out of 11), elevated expression of ®bulin-1 can suppress the ability of ®brosarcoma-derived cells to proliferate in soft agar and to delay the tumorigenicity in vivo. The mechanisms underlying the observed eects have not yet been elucidated. However, a number of studies regarding the role of other ECM molecules in transformation indicate that there is a good correlation between the loss of speci®c ECM molecules and the acquisition of transformed phenotypes in vitro and tumorigenicity in vivo. For instance, hybrid cells formed by fusion of mouse melanoma cells and normal mouse ®broblasts are not malignant. However, inhibition of ®bronectin synthesis in such hybrids by an antisense strategy causes the cells to become tumorigenic (Steel and Harris, 1989) . Conversely, addition of puri®ed ®bronectin to Herpes simplex virus-transformed hamster ®broblasts can restore normal morphology and adhesive properties characteristic of normal cells (Ali et al., 1997) . Overexpression of ®bronectin in human ®brosarcoma-derived HT1080 cells with increased deposition of ®bronectin on the cell surface leads to reduced anchorage-independent growth and tumorigenicity (Akamatsu et al., 1996) . A recent study shows that expression of SPARC, an ECM protein, in ovarian cancer cells results in a signi®cant decrease in cancer cell growth and tumorigenic potential (Mok et al., 1996) . Collectively, these data demonstrate that certain ECM molecules play an important role in the regulation of malignant transformation. Perturbation in expression of these molecules could lead to global eects by interfering with the formation and stabilization of extracellular matrix structures, or as suggested by Juliano and Haskill (1993) , with normal cell growth signaling pathways that act through the extracellular matrix.
An important conclusion that can be drawn from our results is that loss of ®bulin-1D plays a role in invasion and perhaps metastasis. One possible model is that ®bulin-1D negatively regulates the ability of cells to interact with migration-promoting ECM components, thereby inhibiting cellular migration. The ability of ®bulin-1 to interact with several adhesive and migration-promoting proteins, such as ®bronectin and laminin, has been established (Balbona et al., 1992; Pan et al., 1993b) . It is possible that ®bulin-1 binding to these proteins interferes with the ability of cells to derive migratory stimuli. We know that the ®bulin-1 binding site in ®bronectin is located within type III repeats 13 and 14 (Balbona et al., 1992) . This region lies adjacent to the Arg-Gly-Asp (RGD)-containing type III 10 adhesive domain and the CSIII adhesive domain (Argraves and . These domains mediate cellular interaction with ®bronectin via a wide array of integrins, including a5b1 binding to the RGD site and a4b1 binding to the CSIII site. It is possible that the binding of ®bulin-1 to ®bronectin interferes with integrin binding to either or both of these sites. The ®bulin-1 binding site with Engelbreth-HolmSwarm tumor laminin has been mapped to a site contained within the E3 fragment (Pan et al., 1993b; Brown et al., 1994) , a fragment derived from the carboxy terminus of the a chain. This domain has been shown to mediate integrin a3b1 binding (Gehlsen et al., 1989 (Gehlsen et al., , 1992 and lies in the vicinity of binding sites for the integrins a6b1 (Aumailley et al., 1990; Hall et al., 1990; Sonnenberg et al., 1991) and a7b1 (Kramer et al., 1991; von der Mark et al., 1991) . In addition, the laminin receptor dystroglycan binds to the E3 fragment (Gee et al., 1993) . Studies are under way to determine whether ®bulin-1 modulates any of these receptoradhesive protein interactions.
Interestingly, in contrast to our ®ndings, Clinton et al. (1996) recently reported that estrogens increase the expression of ®bulin-1 in human ovarian cancer cells. They suggest that the augmented ®bulin-1 expression facilitates ovarian tumor cell invasion. However, they have not yet carried out studies to test this hypothesis. It may also be that estrogen-augmented ®bulin-1 expression acts to inhibit tumor cell migration. Clearly, additional experiments are required to determine the role that ®bulin-1 plays in the movement and growth of various types of tumor cells.
In summary, by using dierential mRNA display we have identi®ed ®bulin-1 as a gene which is downregulated in a human ®broblastic cell strain transformed in culture. We have found that the ®bulin-1D protein is expressed at a low or completely undetectable level in a number of human ®broblastic cells transformed in culture as well as in a number of human tumor-derived cell lines. We have demonstrated that increased expression of ®bulin-1D from a transfected gene in human ®brosarcoma-derived cell lines reduced anchorage-independent growth and delayed tumor growth in athymic mice. Furthermore, the invasive ability of these cells was greatly suppressed. These ®ndings indicate that the loss of ®bulin-1D expression contributes to the transformation and progression of human ®brosarcoma. This study points to the importance of recent studies that have shown that ECM molecules can directly regulate critical cellular process such as growth, dierentiation and apoptosis (Jones et al., 1993; Lin and Bissell, 1993; Meredith et al., 1993; Frisch and Francis, 1994) . Further research in various types of cells will be required to address the precise mechanism by which ECM contributes to the transformation process.
Materials and methods
Cells and cell culture
The in®nite life span human ®broblast cell strain MSU-1.1 and its derivative cell lines were routinely cultured in Eagle's minimum essential medium, modi®ed by addition of L-aspartic acid (0.2 mM), L-serine (0.2 mM) and pyruvate (1 mM) and supplemented with 10% supplemented calf serum (SCS) (Hyclone Laboratory, Logan, UT), Fibulin-1D suppresses invasion and tumorigenicity J Qing et al penicillin (100 units/ml), streptomycin (100 mg/ml) and hydrocortisone (1 mg/ml) (complete medium) at 378C in a humidi®ed incubator containing 5% CO 2 in air.
Growth rate
Growth curves were obtained by plating 2610 4 cells per 60 mm diameter dish and harvesting triplicate dishes on day 1, 3, 4, 5 and 7. The total number of cells per dish was determined using an Elzone Counter. The exponential growth phase of the growth curve was used to calculate the population doubling time.
Dierential mRNA display
Non-tumorigenic human ®broblast cell strain MSU-1.1 and its malignant derivative cell line 6A/SB1 were used as sources of RNA. Total RNA from cells in exponential growth was extracted using RNAzolB (Tel-Test, Friendswood, TX). Dierential mRNA display was performed as described (Liang and Pardee, 1992; Liang et al., 1993) with slight modi®cations. Brie¯y, total RNA (0.2 mg) from each cell line was reverse transcribed with each of the four degenerate oligo (dT) primers T 12 MA, T 12 MT, T 12 MG and T 12 MC (where M may be dG, dC, or dA), followed by PCR ampli®cation of the cDNA in the presence of [a-
35 S]dATP (Dupont, Wilmington, DE) using the corresponding T 12 MN as the 3' primer and one of the arbitrary 10-mers (OPA1-20, Operon Technologies, Alameda, CA) as the 5' primer. The PCR thermal cycle paramters were as follows: 948C for 30 s, 408C for 2 min, and 728C for 30 s for 40 cycles, followed by extension at 728C for 7 min. PCR products were separated in a 6% denaturing polyacrylamide gel. Gels were dried without ®xation and exposed to Kodak XAR ®lm. To con®rm the results, reactions showing dierentially expressed mRNAs in MSU-1.1 and 6A/SB1 cells were repeated in duplicate using two independent RNA preparations. The cDNA fragments representing uniquely expressed mRNAs were excised from the dried gels and reampli®ed by PCR using the same set of primers originally used. The PCR products were run on a 1.5% agarose gel, and the bands of the appropriate size were cut from the gel and puri®ed using QIAquick gel extraction kit (Qiagen, Chatsworth, CA).
Subcloning and DNA sequencing
The puri®ed DNA was used as a probe for Northern blot analysis or subcloned into the pCRII vector by the TA cloning method (Invitrogen, San Diego, CA) according to the manufacturer's instructions. Subsequent identi®cation of insert-containing clones was carried out by the dotblot DNA hybridization procedure described by Callard et al. (1994) . The subcloned cDNA inserts were again used as probes for Northern analysis to con®rm the dierential expression. DNA sequencing was performed directly from the TA cloning vector with the SP6 and the T7 primer using the Fidelity DNA sequencing system (Oncor, Gaithersburg, MD). DNA database searches were performed using the GCG FASTA program (Genetics Computer Group, Madison, WI) or the BLAST program from National Center for Biotechnology Information.
Northern blot analysis
Total RNA (15 mg) was electrophoresed on a denaturing formaldehyde agarose gel (1.2%), transferred to Hybond-N membrane (Amersham, Arlington Heights, IL) by the downward capillary transfer technique (Chomczynski, 1992 ) using a 20-fold concentration of standard saline citrate buer, and ®xed by u.v. crosslinking (UV Stratalinker 2400, Stratagene, La Jolla, CA). DNA probes were radiolabeled by the random primed labeling method (Feinberg and Vogelstein, 1983) . Northern hybridization was performed at 428C overnight in 50% formamide containing 56SSPE, 56Denhardt's solution, 0.1% sodium dodecyl sulphate (SDS) and 0.1 mg/ml salmon sperm DNA. The blots were then washed twice in 16SSPE, 0.1% SDS at 428C, and a third wash was carried out in 0.256SSPE with 0.1% SDS at 558C. To strip the membrane for reprobing, the blots were treated with boiling 0.1% SDS solution and allowed to cool to room temperature. Variation in RNA loading per lane was evaluated by probing with glyceraldehyde3-phosphate dehydrogenase (GAPDH) cDNA as the control.
Preparation of cell lysates and conditioned medium
Cells were grown in 100 mm-diameter dishes in Eagle's medium containing 10% SCS until subcon¯uent. To harvest the cells, the cell monolayer was quickly washed four times with cold phosphate buered saline (PBS), and the cells were lysed for 20 min on ice in 0.5 ml of RIPA buer composed of 50 mM Tris-HCl, pH 7.2, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholic acid, 2 mM phenylmethylsulfonyl¯uoride (PMSF), 1 mM EDTA and 0.15 units/ml aprotinin. The cell lysates were collected with a rubber scraper, centrifuged at 14 000 g for 15 min at 48C, and the protein concentration of the supernatant was determined using a bicinchoninic acid protein assay kit (Pierce Chemical, Rockford, IL) with bovine serum albumin as the protein standard. The cell lysates were used immediately or stored at 7808C until use. To collect conditioned medium, nearly con¯uent cells cultured in 60 mm-diameter dishes (i.e. *2610 6 cells) were washed four times with Eagle's medium, and incubated for another 48 h in 4 ml of complete medium without serum. The conditioned medium was collected, and PMSF (®nal concentration, 1 mM) and aprotinin (0.15 units/ml) were added, and the medium was centrifuged at 14 000 g for 5 min to remove cell debris. A second duplicate dish for each sample was used to prepare cell lysate as described, and the protein concentration of the cell extract was used to normalize the volume of conditioned medium used for Western blot analysis.
Western blot analysis of ®bulin-1
Aliquots of cell lysates containing 20 mg of protein or 50 ml of the conditioned medium were mixed with the sample buer (0.05 M Tris-HCl, pH 6.9, 9% glycerol, 2.3% SDS and 0.1% bromophenol blue) without a reducing agent, and the proteins were separated on a 10% SDS/polyacrylamide gel. The proteins were then electroblotted onto an Immobilion-P membrane (Millipore, Bedford, MA). The blots were blocked for 2 h at room temperature in Tris-buered saline (20 mM TrisHCl, pH 7.6, 137 mM NaCl) containing 0.1% (v/v) Tween 20 and 5% (w/v) non-fat dry milk (blocking solution), and then incubated for 2 h at room temperature with the mouse monoclonal anti-®bulin-1 IgG 3A11 diluted 1 : 20 000 in the same solution. This antibody was generated as part of an earlier study (Argraves et al., 1990) . The blots were washed several times and then incubated with horseradish peroxidase-conjugated goatanti-mouse IgG (Boehringer Mannheim, Indianapolis, IN) that had been diluted 1 : 3000 with blocking solution. Enhanced chemiluminescence (Amersham, Arlington Heights, IL) was used according to the manufacturer's recommendations to detect the signal. 
Plasmid construction and transfection
A 2.3 kb EcoRI fragment of pBluescript-Fibulin-1D, containing the entire coding sequence of human ®bulin-1D, was inserted into the unique EcoRI cloning site of the mammalian expression vector pBABE-Puro (Morgenstern and Land, 1990) under the control of Moloney murine leukemia virus long terminal repeat, generating the plasmid pPuro-Fibulin1D. The sense orientation of the cloned fragment was con®rmed by restriction mapping. To produce stably transfected cell lines, cells in exponential growth were plated in 100 mm dishes (2610 5 cells/dish). After 18 ± 24 h, 2 mg of plasmid DNA was transfected into the cells using lipofectamine (GIBCO, Gaithersburg, MD) according to the manufacturer's instructions. Transfected cells were selectively grown in culture medium containing 0.5 mg/ml puromycin (Sigma, St Louis, MO) for 2 ± 3 weeks. Drug-resistant clones were randomly selected and subcloned individually for further study.
Anchorage independence assay
For each cell line or strain, 2610 4 cells were plated at 5000 cells per 60 mm-diameter dish in a top layer of 0.33% agarose in McM medium containing 2% fetal calf serum, essentially as described by Hurlin et al. (1989) . The agarose plates were maintained at 378C in a humidi®ed incubator with 3% CO 2 in air. Each week the medium over the top layer of agarose was removed and fresh McM medium with 2% fetal calf serum was added. At the end of 14 days for 6A/SB1 cells and their transfectants or 21 days for SHAC cells and their transfectants, the cells were ®xed with 2.5% glutaraldehyde. Photomicrographs covering 0.7 cm 2 were made of representative ®elds from each dish. All colonies greater than 100 mm in diameter were scored and the size of each colony was recorded. The frequency of colonies of a given size in this area from each dish was averaged, and the data were expressed per 5000 cells assayed.
In vitro invasion assay
The invasiveness of SHAC cells, 6A/SB1 cells and their transfectants was assayed by a modi®ed Boyden Chamber Matrigel method (Albini et al., 1987) according to the manufacturer's instructions (Collaborative Biomedical Product-Becton Dickinson, Bedford, MA). The cells to be studied were washed with PBS three times and harvested by short exposure to 5 mM EDTA. Cells were washed once with Eagle's medium, and 7610 5 cells in Eagle's medium containing 0.1% BSA were seeded onto the control uncoated ®lters (8 mm pore size) or matrigelcoated ®lters in Biocoat Matrigel invasion chambers. Eagle's medium (2.5 ml) containing 0.1% BSA and 10 mg/ml platelet-derived growth factor (Sigma) was added to the lower compartment. After incubation at 378C for 48 h (for 6A/SB1 cells and its transfectants) or 72 h (for SHAC cells and its transfectants), the ®lters were ®xed in ethanol and stained with 1% crystal violet. Cells that invaded the lower surface of the ®lters were counted under a light microscope. Each assay was done in triplicate.
Tumorigenicity assay
BALB/c athymic mice 6 weeks of age were injected with 1610 6 cells in 0.2 ml of serum-free Eagle's medium subcutaneously in the left front and right hind¯ank regions. Tumor dimensions were measured twice weekly using a vernier caliper, and the size of the tumors was calculated using the formula for the volume of a hemiellipsoid, the geometric ®gure most nearly approximating the shape of the tumor: Volume=0.52366length6width6height (Rockwell et al., 1972) .
